← All indications
Anemia, Refractory, with Excess of Blasts
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
Drugs by status
Approved for this indication (2)
Phase 3 trials (1)
Phase 2 trials (3)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 3 Indications (22)
- Astellas
- Eli Lilly
- Onconova Therapeutics, Inc.
- Kanisa Pharmaceuticals
- National Cancer Institute (NCI)
- University of Pennsylvania
- Eastern Cooperative Oncology Group
- Gottfried Wilhelm Leibniz Universität Hannover
- Indiana University
- Southwest Oncology Group
- University of Hamburg
- University of Witten/Herdecke
- Cardiff University
- University of Ulm
- University of Freiburg
- Ludwig Maximilians University
- J. W. Goethe University
- Erasmus University Rotterdam
- HOVON - Dutch Haemato-Oncology Association
- Ev. Krankenhaus Essen-Werden
- Ghent University
- Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
Organization Involved with Phase 2 Indications (21)
- Jazz Pharmaceuticals
- Seattle Genetics
- Celgene
- IGF Oncology, LLC
- Sunesis Pharmaceuticals
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Emory University
- University of Washington
- Johns Hopkins University
- North Central Cancer Treatment Group
- Thomas Jefferson University
- University of Michigan
- University of Rochester
- Mayo Clinic
- Shandong University
- University of Minnesota
- City of Hope National Medical Center
- Mesoblast, Inc.
- University of Texas at Houston
- Yeshiva University